3rd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$508,363
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Free Trade Agrements, including but not limited to the Trans-Pacific Partnership FTA Any matters related to international activities with regard to access to generic medicines

LobbyistCovered position, as disclosed
BILL HEAD New —
KATHLEEN D JAEGER —
CHARLES L KINNEY —
JASON R MONEY —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC)

Copyright/Patent/Trademark CPT

Patent Reform, including, but not limited to: S.515, S.610, and H.R.1260 Patent Settlements/Reverse Payments/Exclusionary Payments, including, but not limited to: S.369 and H.R.1706 Legislation relating to patent term extensions Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
BILL HEAD New —
KATHLEEN D JAEGER —
CHARLES L KINNEY —
JASON R MONEY —

Contacted: SENATE; Federal Trade Commission (FTC); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 515 (111th), S. 369 (111th), S. 610 (111th), H.R. 1706 (111th), H.R. 1260 (111th)

Medicare/Medicaid MMM

Medicaid Reimbursement Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs Average Manufacture Price (AMP)/AMP Publication Medicare Part D Drug Program, expanding rebates to Part D program

LobbyistCovered position, as disclosed
BILL HEAD New —
KATHLEEN D JAEGER —
CHARLES L KINNEY —
JASON R MONEY —

Contacted: White House Office; SENATE; U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Generic Drug User Fees Funding for FDA, including, but not limited to any proposal relating to funding for the Office of Generic Drugs FY2010 Presidential Budget Request FY2010 Congressional Budget and Appropriations

LobbyistCovered position, as disclosed
BILL HEAD New —
KATHLEEN D JAEGER —
CHARLES L KINNEY —
JASON R MONEY —

Contacted: SENATE; U.S. Trade Representative (USTR); White House Office; Commerce, Dept of (DOC); Federal Trade Commission (FTC); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Pharmacy PHA

Generic Biologics, including but not limited to: H.R.1427, H.R.1548, and S.726 Prescription Drug Safety Counterfeit Drugs/Import Safety/Pedigree, such as: H.R.759 Authorized Generics, including, but not limited to: S.501 and H.R.573 Prescription Drug Importation/Re-Importation Any other matters that relate to access to generic drugs

LobbyistCovered position, as disclosed
BILL HEAD New —
KATHLEEN D JAEGER —
CHARLES L KINNEY —
JASON R MONEY —

Contacted: U.S. Trade Representative (USTR); Congressional Budget Office (CBO); SENATE; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Commerce, Dept of (DOC); White House Office

Bills named: H.R. 573 (111th), H.R. 1427 (111th), S. 501 (111th), H.R. 759 (111th), S. 726 (111th), H.R. 1548 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.